Enteroporc Coli

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Inactivated fimbrial adhesins of Escherichia coli F4ab, Inactivated fimbrial adhesins of Escherichia coli F4ac, Inactivated fimbrial adhesins of Escherichia coli F5, Inactivated fimbrial adhesins of Escherichia coli F6

Available from:

CEVA Santé Animale

ATC code:

QI09AB02

INN (International Name):

Neonatal piglet colibacillosis vaccine (recombinant, inactivated)

Therapeutic group:

svinje

Therapeutic area:

Imunološke za suidae

Therapeutic indications:

For the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by Escherichia coli strains expressing the fimbrial adhesins F4ab, F4ac, F5 and F6.

Product summary:

Revision: 1

Authorization status:

odobren

Authorization date:

2021-01-06

Patient Information leaflet

                                13
B. UPUTA O VMP
14
UPUTA O VMP:
ENTEROPORC COLI SUSPENZIJA ZA INJEKCIJU ZA SVINJE
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
SERIJE U PROMET, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet:
Ceva Santé Animale
10 av. de La Ballastière
33500 Libourne
Francuska
Proizvođač odgovoran za puštanje serije u promet:
IDT Biologika GmbH
Am Pharmapark
06861 Dessau-Rosslau
Njemačka
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Enteroporc COLI suspenzija za injekciju za svinje
3.
KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNE(IH) TVARI I DRUGIH
SASTOJAKA
Jedna doza (2 ml) sadrži:
DJELATNE TVARI:
Inaktivirani fimbrijski adhezini iz
_Escherichia coli_
:
F4ab
≥ 23 rU/ml*
F4ac
≥ 19 rU/ml*
F5
≥ 13 rU/ml*
F6
≥ 37 rU/ml*
* sadržaj fimbrijskih adhezina u relativnim jedinicama po ml,
određeno testom ELISA u odnosu na interni
standard
ADJUVANT:
Aluminij (u obliku hidroksida)
2,0 mg/ml
Žućkasta suspenzija.
4.
INDIKACIJE
Za pasivnu imunizaciju potomaka aktivnom imunizacijom gravidnih
krmača i nazimica radi smanjenja
kliničkih znakova (teškog proljeva) i smrtnosti uzrokovanih sojevima
_E. coli_
koji ispoljavaju adhezine
F4ab, F4ac, F5 i F6.
Početak imunosti (nakon uzimanja kolostruma): unutar 12 sati nakon
okota
Trajanje imunosti (nakon uzimanja kolostruma): prvi dani života
15
5.
KONTRAINDIKACIJE
Nema.
6.
NUSPOJAVE
Na dan cijepljenja vrlo često se javilo prolazno povećanje tjelesne
temperature (prosječno 0,5 °C, kod
pojedinih svinja do 2 °C) koja se vratila na normalnu unutar 24 sata.
Vrlo često su bili uočeni prolazna oteklina i crvenilo na mjestu
injekcije (prosječno 2,8 cm, kod
pojedinih svinja do 8 cm) koji su bez tretiranja nestali unutar 7
dana.
Često je bilo uočeno blago depresivno ponašanje na dane
cijepljenja.
Učestalost nuspojava je određena sukladno sljedećim pravilima:
-
vrlo česte (više od 1 na 10 tretiranih životinja pokazuju
nuspojavu(e))
-
česte (više od 1 ali manje od 10 životinja na 100 tr
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Enteroporc COLI suspenzija za injekciju za svinje
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Svaka doza (2 ml) sadrži:
DJELATNE TVARI:
Inaktivirani fimbrijski adhezini iz
_Escherichia coli_
:
F4ab
≥ 23 rU/ml*
F4ac
≥ 19 rU/ml*
F5
≥ 13 rU/ml*
F6
≥ 37 rU/ml*
* sadržaj fimbrijskih adhezina u relativnim jedinicama po ml,
određen testom ELISA u odnosu na
interni standard
ADJUVANT:
Aluminij (u obliku hidroksida)
2,0 mg/ml
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
3.
FARMACEUTSKI OBLIK
Suspenzija za injekciju.
Žućkasta suspenzija.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Svinje (gravidne krmače i nazimice).
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Za pasivnu imunizaciju potomaka aktivnom imunizacijom gravidnih
krmača i nazimica radi smanjenja
kliničkih znakova (teškog proljeva) i smrtnosti uzrokovanih sojevima
_Escherichia coli_
koji ispoljavaju
fimbrijske adhezine F4ab, F4ac, F5 i F6.
Početak imunosti (nakon uzimanja kolostruma): unutar 12 sati nakon
okota
Trajanje imunosti (nakon uzimanja kolostruma): prvi dani života.
4.3
KONTRAINDIKACIJE
Nema.
4.4
POSEBNA UPOZORENJA ZA SVAKU OD CILJNIH VRSTA ŽIVOTINJA
Cijepiti samo zdrave životinje.
4.5
POSEBNE MJERE OPREZA PRILIKOM PRIMJENE
3
Posebne mjere opreza prilikom primjene na životinjama
Nije primjenjivo.
Posebne mjere opreza koje mora poduzeti osoba koja primjenjuje
veterinarsko-medicinski proizvod na
životinjama
Nema.
4.6
NUSPOJAVE (UČESTALOST I OZBILJNOST)
Na dan cijepljenja vrlo često se javilo prolazno povećanje tjelesne
temperature (prosječno 0,5 °C, kod
pojedinih svinja do 2 °C) koja se vratila na normalnu unutar 24 sata.
Vrlo često su bili uočeni prolazna oteklina i crvenilo na mjestu
injekcije (prosječno 2,8 cm, kod
pojedinih svinja do 8 cm) koji su bez tretiranja nestali unutar 7
dana.
Često je bilo uočeno blago depresivno ponašanje na dane
cijepljenja.
Učestalost nuspojava je određena sukladno sljedećim pravil
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 12-05-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 12-05-2021
Public Assessment Report Public Assessment Report Bulgarian 14-04-2021
Patient Information leaflet Patient Information leaflet Spanish 12-05-2021
Public Assessment Report Public Assessment Report Spanish 14-04-2021
Patient Information leaflet Patient Information leaflet Czech 12-05-2021
Public Assessment Report Public Assessment Report Czech 14-04-2021
Patient Information leaflet Patient Information leaflet Danish 12-05-2021
Public Assessment Report Public Assessment Report Danish 14-04-2021
Patient Information leaflet Patient Information leaflet German 12-05-2021
Public Assessment Report Public Assessment Report German 14-04-2021
Patient Information leaflet Patient Information leaflet Estonian 12-05-2021
Public Assessment Report Public Assessment Report Estonian 14-04-2021
Patient Information leaflet Patient Information leaflet Greek 12-05-2021
Public Assessment Report Public Assessment Report Greek 14-04-2021
Patient Information leaflet Patient Information leaflet English 12-05-2021
Public Assessment Report Public Assessment Report English 14-04-2021
Patient Information leaflet Patient Information leaflet French 12-05-2021
Public Assessment Report Public Assessment Report French 14-04-2021
Patient Information leaflet Patient Information leaflet Italian 12-05-2021
Public Assessment Report Public Assessment Report Italian 14-04-2021
Patient Information leaflet Patient Information leaflet Latvian 12-05-2021
Public Assessment Report Public Assessment Report Latvian 14-04-2021
Patient Information leaflet Patient Information leaflet Lithuanian 12-05-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 12-05-2021
Public Assessment Report Public Assessment Report Lithuanian 14-04-2021
Patient Information leaflet Patient Information leaflet Hungarian 12-05-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 12-05-2021
Public Assessment Report Public Assessment Report Hungarian 14-04-2021
Patient Information leaflet Patient Information leaflet Maltese 12-05-2021
Public Assessment Report Public Assessment Report Maltese 14-04-2021
Patient Information leaflet Patient Information leaflet Dutch 12-05-2021
Public Assessment Report Public Assessment Report Dutch 14-04-2021
Patient Information leaflet Patient Information leaflet Polish 12-05-2021
Public Assessment Report Public Assessment Report Polish 14-04-2021
Patient Information leaflet Patient Information leaflet Portuguese 12-05-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 12-05-2021
Public Assessment Report Public Assessment Report Portuguese 14-04-2021
Patient Information leaflet Patient Information leaflet Romanian 12-05-2021
Public Assessment Report Public Assessment Report Romanian 14-04-2021
Patient Information leaflet Patient Information leaflet Slovak 12-05-2021
Public Assessment Report Public Assessment Report Slovak 14-04-2021
Patient Information leaflet Patient Information leaflet Slovenian 12-05-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 12-05-2021
Public Assessment Report Public Assessment Report Slovenian 14-04-2021
Patient Information leaflet Patient Information leaflet Finnish 12-05-2021
Public Assessment Report Public Assessment Report Finnish 14-04-2021
Patient Information leaflet Patient Information leaflet Swedish 12-05-2021
Public Assessment Report Public Assessment Report Swedish 14-04-2021
Patient Information leaflet Patient Information leaflet Norwegian 12-05-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 12-05-2021
Patient Information leaflet Patient Information leaflet Icelandic 12-05-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 12-05-2021